CGON Stock Analysis: Buy, Sell, or Hold?
CGON - CG Oncology, Inc. Common stock
$69.54
-4.47 (-6.03%)
▼
5d:
+0.51%
30d:
+2.74%
90d:
+34.71%
HOLD
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Smart Money Accumulation
CGON is down 3.5% this week, but smart money is accumulating calls. Top strike: $75 2026-06-18 with 9,724 OI. Call ratio: 100% View Scanner →
Strength: 6.8/10
Get Alerted When CGON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called CGON this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CGON shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CGON shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CGON is currently trading at $69.53, which is considered extended relative to its 30-day fair value range of $66.50 to $70.45.
Technical Outlook: Technically, CGON is in a strong uptrend. Immediate support is located at $65.57, while resistance sits at $75.50. Short-term momentum is weak, with the stock down 6.0% recently.
Market Sentiment: CGON has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $89.64 (+28.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CGON is in a strong uptrend. Immediate support is located at $65.57, while resistance sits at $75.50. Short-term momentum is weak, with the stock down 6.0% recently.
Market Sentiment: CGON has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $89.64 (+28.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$66.50 -
$70.45
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.0%)
- BULLISH: Trading 28.9% below Wall St target ($89.64)
Trading Range Analysis
30-Day Trading Range
$66.50 -
$70.45
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$65.57
Resistance Level
$75.50
Current Trend
Strong Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-25.67
Wall Street Target
$89.64
(+28.9%)
Revenue Growth (YoY)
1982.7%
Share & Embed Analysis
Last updated: May 14, 2026 9:59 PM ET
Data refreshes hourly during market hours. Next update: 10:59 PM
Data refreshes hourly during market hours. Next update: 10:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
James Mulay
SELL
15600 shares
2026-04-17
James Mulay
SELL
1964 shares
2026-03-16
James Mulay
SELL
11145 shares
2026-01-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$550 | 64 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 63 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 60 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 51 HOLD |
